Rohan Palekar Biography and Net Worth

CEO of 89bio

Rohan Palekar serves as Chief Executive Officer, Director of the Company. Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017, where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011, where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles.

What is Rohan Palekar's net worth?: The estimated net worth of Rohan Palekar is at least $3.74 million as of December 6th, 2024. Mr. Palekar owns 471,236 shares of 89bio stock worth more than $3,741,614 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Palekar may own. Additionally, Mr. Palekar receives an annual salary of $1,060,000.00 as CEO at 89bio. Learn More about Rohan Palekar's net worth.
How old is Rohan Palekar?: Mr. Palekar is currently 58 years old. There are 3 older executives and no younger executives at 89bio. Learn More on Rohan Palekar's age.
What is Rohan Palekar's salary?: As the CEO of 89bio, Inc., Mr. Palekar earns $1,060,000.00 per year. Learn More on Rohan Palekar's salary.
How do I contact Rohan Palekar?: The corporate mailing address for Mr. Palekar and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Rohan Palekar's contact information.
Has Rohan Palekar been buying or selling shares of 89bio?: Over the course of the past ninety days, Rohan Palekar has bought $122,950.00 of 89bio stock. Most recently, on Friday, December 6th, Rohan Palekar bought 5,000 shares of 89bio stock. The stock was acquired at an average cost of $7.89 per share, with a total value of $39,450.00. Following the completion of the transaction, the chief executive officer now directly owns 471,236 shares of the company's stock, valued at $3,718,052.04. Learn More on Rohan Palekar's trading history.
Who are 89bio's active insiders?: 89bio's insider roster includes Gregory Grunberg (Director), Ryan Martins (CFO), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.
Are insiders buying or selling shares of 89bio?: In the last twelve months, 89bio insiders bought shares 4 times. They purchased a total of 1,375,000 shares worth more than $20,925,450.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 4,477 shares worth more than $48,172.52. The most recent insider tranaction occured on December, 6th when CEO Rohan Palekar bought 5,000 shares worth more than $39,450.00. Insiders at 89bio own 2.8% of the company. Learn More about insider trades at 89bio.
Information on this page was last updated on 12/6/2024.

Rohan Palekar Insider Trading History at 89bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2024	Buy	5,000	$7.89	$39,450.00	471,236
11/22/2024	Buy	10,000	$8.35	$83,500.00	466,236
2/26/2024	Sell	4,477	$10.76	$48,172.52	486,889
6/5/2023	Sell	15,000	$20.00	$300,000.00	286,978
3/23/2023	Sell	15,000	$16.00	$240,000.00	269,080
1/27/2022	Buy	5,000	$7.50	$37,500.00

Rohan Palekar Buying and Selling Activity at 89bio

89bio Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Today's Range

Now: $7.94

$6.60

$7.95

50 Day Range

MA: $8.45

$7.03

$10.45

2 Week Range

Now: $7.94

$6.43

$16.63

Volume

4,504,668 shs

Average Volume

980,337 shs

Market Capitalization

$842.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Rohan Palekar Biography and Net Worth

What is Rohan Palekar's net worth?

How old is Rohan Palekar?

What is Rohan Palekar's salary?

How do I contact Rohan Palekar?

Has Rohan Palekar been buying or selling shares of 89bio?

Who are 89bio's active insiders?

Are insiders buying or selling shares of 89bio?